Sentences with phrase «treatment phase of the study»
Therapists were required to complete a 12 - session course of IPT with a postpartum depressed woman at a satisfactory level of competence and adherence prior to entering the treatment phase of the study.
https://jamanetwork.com/ Not exact matches
«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
Several clinical centres in the USA and Canada recruited four groups of men with CRPC to a phase II study to receive 2550 mg of galeterone orally once a day: 22 men had CRPC that had not metastasised (spread) and had received no previous treatment; 39 men had metastatic CRPC and no previous treatment with abiraterone or enzalutamide; 37 and nine men had metastatic CRPC and had failed treatment with abiraterone and enzalutamide respectively.
«In an earlier phase I clinical study, our group has shown that increasing the dose of radiation delivered daily with high precision and using image guidance may offset the need for chemotherapy in improving survival, and it may also improve quality of life measures by reducing treatment periods in half.
In the phase II study, 18 of 24 patients survived at least 12 months; with standard treatment, only about half of patients survive one year.
The study was a randomized phase II trial testing whether the addition of local treatment, in the form of consolidative radiation therapy, to the standard treatment of systemic therapy improved progression - free survival for patients with limited metastatic NSCLC.
«Despite its narrow therapeutic window and the emergence of proprietary alternatives, U.S. FDA - approved lithium therapeutics are still regarded as the «gold standard» for the treatment of the manic phase of bipolar disorder,» said study lead author Adam J. Smith, PhD, a neuroscientist at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, at USF Health.
The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on April 19.
This study is the first phase of a larger initiative to develop and pilot test Critical Time Intervention, a transitional assistance model for individuals leaving residential substance abuse treatment.
Earlier phases of the study have shown it to be effective in treating individual cases of trachoma, and the trial is now looking into what treatment strategies will be required to stop the infection spreading and thereby eradicate the disease within the country.
The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»
Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.
With approximately two - thirds of responders to AF - 219 treatment showing more than a 50 % reduction in cough frequency, we plan to advance the development of AF - 219 by initiating a Phase 2b study in patients with chronic cough early next year and to initiate other studies in preparation for registration studies.»
«The percentage of patients who benefited from treatment with hu14.18 K322A was unusual for a Phase I study.»
Guselkumab, a fully human monoclonal antibody targeting IL - 23, in this Phase 2 study for the treatment of PsA, was well tolerated with no unexpected safety findings in this patient population.2 Guselkumab is now being pursued in a Phase 3 development programme for psoriatic arthritis.
A Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
14255: STAT3 Signaling During Chemo - Radiation for Squamous Cell Carcinoma of the Head and Neck 14340: A Phase II, Randomized, Open - Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) 14258: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.
A Phase Ib, Open - Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium - 223 Dichloride in Patients with Castrate - Resistant Prostate Cancer who have Progressed Following Treatment with an Androgen Pathway Inhibitor
A Phase 3, Multicenter, Randomized, Open - Label Study of Guadecitabine (SGI - 110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Phase III Study of ADXS11 - 001 Administered Following Chemoradiation As Adjuvant Treatment For High Risk Locally Advanced Cervical Cancer
The newly issued patents (U.S. Patent Nos. 9493515 and 9493516) broadly cover Proclara's core technology, including methods of treating protein misfolding diseases and pharmaceutical compositions comprising the company's lead molecule, NPT088, a GAIM - Ig fusion protein currently being evaluated in a Phase 1b study for the treatment of Alzheimer's disease.
A novel targeted approach to the treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI - 0501: first results from a pilot phase 2 study in children with primary HLH
The phase 1 study of metastatic prostate cancer patients found no major treatment related toxicities or any autoimmune pathology.
In this phase - 1 study, fifteen of 21 patients who had previously relapsed or failed to respond to CD19 CAR T - cell treatment went into remission.
She is institutional principal investigator of the Phase I Consortium Study in New Agents in Neuroblastoma Treatment and directs NIH - funded work on effects of SPARC (secreted protein acidic and rich in cysteine, an amino acid) on neuroblastoma tumor growth and blood vessel formation.
Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.
Phase 1 clinical trials give patients at University of Michigan access to pivotal early - stage studies, connecting families to novel treatment therapies to patients before they are widely available.
More than half of patients (58 %) in both study phases had grade 3 or worse treatment - related adverse events.
«A number of these assays and associated bioinformatics software have been validated for use in Invivoscribe's own «LabPMM» clinical laboratories, and they are currently being used by leading cancer treatment centers and pharmaceutical partners, both to optimize treatments for patients, and to stratify, enroll, and track residual disease in patients in international phase II and phase III clinical studies.
In 2009, bevacizumab (Avastin ®) was granted accelerated approval for the treatment of GBM patients whose cancers had recurred, based on results from two phase II studies.
Amgen has communicated with regulatory authorities and is in the process of notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as a separate ongoing Phase 2 trial in locally advanced pancreatic cancer.
February 21, 2006 deCODE genetics (Nasdaq: DCGN) today announced top - line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD).
As part of an emerging treatment strategy, drugs derived from JQ1 are currently under study in early - phase human cancer trials.
Omecamtiv mecarbil is a selective, small - molecule currently being studied in a Phase 3 clinical trial of ~ 8000 patients as a potential treatment for heart failure with reduced ejection fraction in collaboration with Amgen and in partnership with Servier.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutaPhase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutaphase chronic myeloid leukemia (CP - CML) with a T315I mutation.
«A number of our assays and associated bioinformatics software are currently being used by leading cancer centers and pharmaceutical partners in support of optimizing treatments for patients, and to stratify, enroll, and track MRD in patients in international phase II and phase III clinical studies.
The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).
«Patients in Phase I clinical studies are the first to potentially benefit from a new treatment,» said Cohn, a leading expert in the study and treatment of neuroblastoma, a malignant solid tumor that forms in the nervous system outside the brain.
The drug, a monoclonal antibody called ipilimumab, is the first treatment of any kind ever shown in a large, randomized phase III clinical study (study MDX010 - 20) to improve overall survival in patients with metastatic melanoma who no longer respond to standard therapy.
The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on Sunday, April 19 (Abstract #CT137).
Given there are no studies (at least that I am aware of) that support a strictly PB treatment for ED patients, I currently do not endorse such eating during the active recovery phase.
Distinguished Principals play a critical role in this phase of the ACS Project (2016 - 2019), serving as coaches to the «treatment» principals in the coaching study.
Home / NEWS & MEDIA / Pfizer Animal Health and American Humane Association Conclude First Phase of Study Evaluating the Benefits of Animal - Assisted Therapy for Children Undergoing Cancer Treatment
Pfizer Animal Health and American Humane Association Conclude First Phase of Study Evaluating the Benefits of Animal - Assisted Therapy for Children Undergoing Cancer Treatment
Co-author of the Bisgrove Phase I clinical trial published in fall 2009: A Pilot Study Using Molecular Profiling of Patients» Tumors to Find Potential Targets and Select Treatments for their Refractory Cancers.
Among the patients who did continue on the study after withdrawing from the psychoeducation group, the reasons for abandoning it were manic recurrence (7 patients), problems with the group time table (2 patients found a new job during the treatment phase and could not continue coming to the sessions), consent withdrawal or nonacceptance of the group rules (1 patient), interpersonal problems with other group members (1 patient), and depressive recurrence (1 case).
We will exclude trials with treatment duration of less than 4 weeks, because the onset of benefit for most antidepressants often takes at least 4 weeks.31 If a study presents data for more than one time point within our predefined acute phase window or beyond 16 weeks, the 8 week (or the closest to 8 week) will be taken as the time.